Literature DB >> 6826101

Symptoms of irritable bowel syndrome in ulcerative colitis in remission.

B Isgar, M Harman, M D Kaye, P J Whorwell.   

Abstract

The prevalence of symptoms suggestive of a motility disturbance similar to the irritable bowel syndrome was investigated in 98 patients with ulcerative colitis in remission, and a similar number of age- and sex-matched healthy controls. Thirty-three per cent of patients compared with 7% of controls fulfilled the criteria for such a syndrome (p<0.01). Contrary to expectations these symptoms were not confined to patients with distal disease. Other symptoms such as constipation were also very common in the colitic group (31%).

Entities:  

Mesh:

Year:  1983        PMID: 6826101      PMCID: PMC1419934          DOI: 10.1136/gut.24.3.190

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  3 in total

1.  Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk.

Authors:  J A Ritchie; S C Truelove
Journal:  Br Med J       Date:  1979-02-10

2.  Towards positive diagnosis of the irritable bowel.

Authors:  A P Manning; W G Thompson; K W Heaton; A F Morris
Journal:  Br Med J       Date:  1978-09-02

3.  Functional bowel disorders in apparently healthy people.

Authors:  W G Thompson; K W Heaton
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

  3 in total
  71 in total

Review 1.  The functional gastrointestinal disorders and the Rome II process.

Authors:  D A Drossman
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

2.  British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.

Authors:  J Jones; J Boorman; P Cann; A Forbes; J Gomborone; K Heaton; P Hungin; D Kumar; G Libby; R Spiller; N Read; D Silk; P Whorwell
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

3.  The putative role of inflammation in the irritable bowel syndrome.

Authors:  S M Collins; T Piche; P Rampal
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

4.  Guidelines for the investigation of chronic diarrhoea, 2nd edition.

Authors:  P D Thomas; A Forbes; J Green; P Howdle; R Long; R Playford; M Sheridan; R Stevens; R Valori; J Walters; G M Addison; P Hill; G Brydon
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

5.  Ulcerative colitis patients in remission have an altered secretory capacity in the proximal colon despite macroscopically normal mucosa.

Authors:  J K Gustafsson; G C Hansson; H Sjövall
Journal:  Neurogastroenterol Motil       Date:  2012-06-24       Impact factor: 3.598

6.  Acute distal colitis impairs gastric emptying in rats via an extrinsic neuronal reflex pathway involving the pelvic nerve.

Authors:  H U De Schepper; J G De Man; L Van Nassauw; J-P Timmermans; A G Herman; P A Pelckmans; B Y De Winter
Journal:  Gut       Date:  2006-09-14       Impact factor: 23.059

7.  Coexistent chronic idiopathic intestinal pseudo obstruction and inflammatory bowel disease.

Authors:  B Ohlsson; F-T Fork; B Veress; E Toth
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

Review 8.  Best practice in primary care pathology: review 6.

Authors:  W S A Smellie; J Forth; J J Coleman; W Irvine; P C Dore; G Handley; D G Williams; P J Galloway; K G Kerr; R Herriot; G P Spickett; T M Reynolds
Journal:  J Clin Pathol       Date:  2006-07-05       Impact factor: 3.411

9.  Proposal of a new clinical index predictive of endoscopic severity in ulcerative colitis.

Authors:  Francesco Azzolini; Cristiano Pagnini; Lorenzo Camellini; Antonella Scarcelli; Alberto Merighi; Anna Maria Primerano; Angela Bertani; Aldo Antonioli; Federico Manenti; Gian Piero Rigo
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

10.  Development of colorectal sensitization is associated with increased eosinophils and mast cells in dextran sulfate sodium-treated rats.

Authors:  J M Tobin; L M D Delbridge; R Di Nicolantonio; P Bhathal
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.